Search results
Results from the WOW.Com Content Network
Belimumab, sold under the brand name Benlysta, is a human monoclonal antibody that inhibits B-cell activating factor (BAFF), [6] also known as B-lymphocyte stimulator (BLyS). [7] It is approved in the United States [ 8 ] and Canada, [ 9 ] and the European Union [ 5 ] to treat systemic lupus erythematosus and lupus nephritis.
ATC code L04 Immunosuppressants is a therapeutic subgroup of the Anatomical Therapeutic Chemical Classification System, a system of alphanumeric codes developed by the World Health Organization (WHO) for the classification of drugs and other medical products.
Belimumab [37] Benlysta: mab: human: B-cell activating factor (BAFF) Y: systemic lupus erythematosus without renal or CNS involvement Bemarituzumab [26] mab: humanized: FGFR2: gastric cancer or gastroesophageal junction adenocarcinoma Benralizumab [38] Fasenra: mab: humanized: CD125: Y: asthma Berlimatoxumab [26] mab: human: Staphylococcus ...
Download QR code; Print/export Download as PDF; Printable version; In other projects ... belimumab ; belinostat (USAN, INN) Belix; Bellafoline; Bellatal; Bellergal-S;
Belimumab: GlaxoSmithKline: active lupus nephritis [1] Osimertinib: AstraZeneca: adjuvant therapy after tumor resection in non-small cell lung cancer with EGFR exon 19 deletions or exon 21 L858R mutations Ansuvimab: Ridgeback Biotherapeutics: Ebola Zaire
This monoclonal antibody –related article is a stub. You can help Wikipedia by expanding it.
Atacicept is a recombinant fusion protein designed to inhibit B cells, thereby suppressing autoimmune disease.The designer protein combines the binding site for two cytokines that regulate maturation, function, and survival of B cells – B-lymphocyte stimulator (BLyS) and A proliferation-inducing ligand (APRIL), with the constant region of immunoglobin. [1]
A. Acalabrutinib; Acetohydroxamic acid; Acoramidis; Adagrasib; Adalimumab; Afamelanotide; Afamitresgene autoleucel; Afatinib; Afegostat; Alectinib; Alglucosidase alfa